[go: up one dir, main page]

YU55203A - Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji - Google Patents

Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji

Info

Publication number
YU55203A
YU55203A YU55203A YUP55203A YU55203A YU 55203 A YU55203 A YU 55203A YU 55203 A YU55203 A YU 55203A YU P55203 A YUP55203 A YU P55203A YU 55203 A YU55203 A YU 55203A
Authority
YU
Yugoslavia
Prior art keywords
inflammatory
compounds
conjugates
immune cell
cell specific
Prior art date
Application number
YU55203A
Other languages
English (en)
Inventor
Mladen Merčep
Milan MESIĆ
Linda Tomašković
Marijana Komac
Boška Hrvačić
Stribor Marković
Original Assignee
Pliva D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva D.D. filed Critical Pliva D.D.
Publication of YU55203A publication Critical patent/YU55203A/sh
Publication of RS51308B publication Critical patent/RS51308B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na nova jedinjenja prikazana strukturom I, i na njihove farmaceutske preparate, za lečenje inflamatornih jedinjenja kod ljudi i životinja.[The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
YUP-552/03A 2001-01-09 2002-01-03 Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji RS51308B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20010018A HRP20010018A2 (en) 2001-01-09 2001-01-09 Novel anti-inflammatory compounds

Publications (2)

Publication Number Publication Date
YU55203A true YU55203A (sh) 2006-03-03
RS51308B RS51308B (sr) 2010-12-31

Family

ID=10947235

Country Status (23)

Country Link
US (2) US7446097B2 (sh)
EP (1) EP1351973B1 (sh)
JP (1) JP4474101B2 (sh)
CN (1) CN1269836C (sh)
AR (1) AR035727A1 (sh)
AT (1) ATE462713T1 (sh)
BG (1) BG108073A (sh)
BR (1) BR0206347A (sh)
CA (1) CA2434009C (sh)
CZ (1) CZ20031825A3 (sh)
DE (1) DE60235794D1 (sh)
EA (1) EA007061B1 (sh)
EE (1) EE05333B1 (sh)
ES (1) ES2342364T3 (sh)
GE (1) GEP20053607B (sh)
HR (1) HRP20010018A2 (sh)
HU (1) HUP0500180A3 (sh)
IL (1) IL156673A0 (sh)
PL (1) PL207636B1 (sh)
RS (1) RS51308B (sh)
SK (1) SK9792003A3 (sh)
UA (1) UA77166C2 (sh)
WO (1) WO2002055531A1 (sh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002109169A (ja) * 2000-09-29 2002-04-12 Hitachi Ltd 作業支援方法並びにシステム及び作業支援方法を記録した記録媒体
AU2003211113B2 (en) 2002-02-15 2007-08-09 Merckle Gmbh Antibiotic conjugates
EP1483277A4 (en) * 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS
WO2003070173A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2004005310A2 (en) 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
RS20050007A (sr) * 2002-07-08 2007-09-21 Glaxo Smith Kline Istraživački Centar Zagreb D.O.O., NOVE NESTEROIDNE-ANTI- INFLAMATORNE SUPSTANCE, KOMPOZICIJE I POSTUPCI ZA NjIHOVU UPOTREBU
ATE429441T1 (de) 2002-07-08 2009-05-15 Glaxosmithkline Zagreb Hybridmoleküle von makroliden mit steroidalen/nicht-steroidalen antientzündlich aktiven molekülen
HRP20030324A2 (en) * 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
JP4737495B2 (ja) * 2004-01-14 2011-08-03 塩野義製薬株式会社 エリスロマイシン誘導体
US20060183696A1 (en) * 2004-08-12 2006-08-17 Pliva-Istrazivacki Institut D.O.O. Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
MX2007001669A (es) * 2004-08-12 2007-04-10 Glaxosmithkline Zagreb Uso de conjugados especificos celulares para el tratamiento de enfermedades inflamatorias del tracto gastrointestinal.
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
ES2337915T3 (es) * 2004-10-27 2010-04-30 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugados con adtividad antiinflamatoria.
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
US20080249034A1 (en) * 2005-03-21 2008-10-09 Zambon S.P.A. Use of Macrolides for Treating Intestinal Inflammation
US20130045939A1 (en) * 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
EP3309166A3 (en) * 2013-01-23 2018-08-22 Sphaera Pharma Pvt. Ltd. 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
EP3795578A3 (en) 2014-07-23 2021-05-26 Sphaera Pharma Pvt. Ltd. Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
GB201520419D0 (en) * 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds
WO2023248010A2 (en) * 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
HU198913B (en) 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
JPH01163124A (ja) * 1987-12-21 1989-06-27 Yamayuu Seikatsushiya:Kk 外用鎮痛消炎消腫消膿剤
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroids
GB9225923D0 (en) 1992-12-11 1993-02-03 Rhone Poulenc Rorer Ltd New compositions of matter
JP2657982B2 (ja) 1992-12-24 1997-09-30 ローン−プーラン・ロレ・リミテツド 新規ステロイド
EP0775489A4 (en) 1994-08-12 1998-05-06 Taisho Pharmaceutical Co Ltd INTERLEUKIN-5 PRODUCTION INHIBITOR
CA2196879A1 (en) 1994-08-12 1996-02-22 Akihiko Hoshino Interleukin-5 production inhibitor
DE19542949A1 (de) 1995-11-17 1997-07-17 Hilti Ag Bolzen zum Eintreiben in harte Aufnahmewerkstoffe
CA2252886C (en) 1996-04-26 2008-02-12 Massachusetts Institute Of Technology Three-hybrid screening assay
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
AU4549999A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses
IT1306205B1 (it) 1999-01-15 2001-05-30 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
EP1483277A4 (en) 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS

Also Published As

Publication number Publication date
HK1065320A1 (en) 2005-02-18
EP1351973B1 (en) 2010-03-31
US20040198677A1 (en) 2004-10-07
EE05333B1 (et) 2010-08-16
US7446097B2 (en) 2008-11-04
SK9792003A3 (en) 2004-01-08
PL207636B1 (pl) 2011-01-31
CN1269836C (zh) 2006-08-16
CZ20031825A3 (cs) 2003-11-12
JP2004518670A (ja) 2004-06-24
EA007061B1 (ru) 2006-06-30
JP4474101B2 (ja) 2010-06-02
DE60235794D1 (de) 2010-05-12
US7928078B2 (en) 2011-04-19
HUP0500180A3 (en) 2009-12-28
CN1491230A (zh) 2004-04-21
WO2002055531A1 (en) 2002-07-18
ATE462713T1 (de) 2010-04-15
UA77166C2 (en) 2006-11-15
PL363478A1 (en) 2004-11-15
EP1351973A1 (en) 2003-10-15
RS51308B (sr) 2010-12-31
BR0206347A (pt) 2004-02-10
HUP0500180A2 (en) 2006-09-28
ES2342364T3 (es) 2010-07-06
CA2434009C (en) 2009-09-29
HRP20010018A2 (en) 2002-12-31
EA200300781A1 (ru) 2003-12-25
AR035727A1 (es) 2004-07-07
CA2434009A1 (en) 2002-07-18
GEP20053607B (en) 2005-09-12
IL156673A0 (en) 2004-01-04
US20090105163A1 (en) 2009-04-23
BG108073A (bg) 2005-05-31
EE200300293A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
YU55203A (sh) Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
TR200102072T2 (tr) İltihap karşıtı maddeler olarak aromatik çok döngülü bileşimler
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
GB0022438D0 (en) Organic Compounds
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
ITRM20020049A1 (it) Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
GB2448255A (en) Compositions and methods relating to treatment of cancer and infectious diseases
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
ATE530184T1 (de) Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption